The Advisory Committee on Immunization Practices (ACIP), which recommends US immunization policy to the Centers for Disease Control and Prevention (CDC), recently held two important meetings. During the February 24-25, 2021 meeting, ACIP reviewed data on vaccines to prevent influenza (flu), hepatitis, pneumococcal disease, shingles, and other diseases. During the emergency meeting on February 28-March 1, 2021, ACIP voted to approve the new Janssen single-dose COVID-19 vaccine.
In this episode of the Schaffner Report, Marla Dalton, executive director and CEO of the National Foundation for Infectious Diseases (NFID), talks with NFID medical director and ACIP liaison, William Schaffner, MD, about the significance of these meetings for healthcare professionals and the public.
As we look ahead to the 2021-2022 flu season, more children will likely be back at school learning in-person and there may be less attention to social distancing and face masks. Flu will be back, and we must prepare …
To learn more about updated immunization recommendations, register for the complimentary NFID webinar, Updates from February 2021 ACIP Meeting, on March 17, 2021.
“As we look ahead to the 2021-2022 respiratory season, we recognize that more children will likely be back at school learning in-person, there may be less attention to social distancing, face masks, and hand hygiene, and family and friends who may have stayed apart throughout the pandemic will reunite. (Influenza) flu will be back, and we must prepare,” said NFID Executive Director and CEO Marla Dalton at the February 24, 2021 ACIP meeting. Read the complete NFID public comment.
To join the conversation and get the latest news on infectious diseases, follow NFID on Twitter, like us on Facebook, follow us on Instagram, visit us on LinkedIn, and subscribe to receive future NFID Updates.
